Skip to content

Preliminary Efficacy Analysis of C Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy

Laparoscopic Proximal Gastrectomy with C Single Flap Plasty Reconstruction for Upper-Third Gastric Cancer: a Randomized Clinical Trial.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06741501
Enrollment
50
Registered
2024-12-19
Start date
2025-01-01
Completion date
2025-06-01
Last updated
2024-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Reflux Esophagitis

Brief summary

The incidence of proximal gastric cancer has increased significantly in recent years. This may be due to weight gain, alcohol consumption, gastroesophageal reflux disease (GERD), and precancerous lesions. With a deeper understanding of the pattern of lymph node metastasis and the emergence of anti-reflux procedures, proximal gastrectomy has gradually received clinical attention. For early-stage upper gastric cancer and esophagogastric combination cancer cases that are expected to have a good prognosis, the ideal surgical procedure should be to preserve the distal stomach to improve the quality of life and to choose a reasonable digestive tract reconstruction method to prevent reflux. The anti-reflux effect of various proximal gastrectomy digestive tract reconstruction methods and the advantages and disadvantages of various surgical procedures are controversial, and the recognized ideal reconstruction method has not yet been established. Therefore, we propose a reconstruction called the C Single Flap Plasty Reconstruction. This study aimed to investigate the efficacy and safety of proximal gastrectomy combined with C Single Flap Plasty Reconstruction in the treatment of gastric cancer.

Interventions

PROCEDUREC Single Flap Plasty Reconstruction

1\. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high C-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site. 2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior esophageal wall to the remnant stomach, the common opening between the esophagus and the stomach is closed. 3. Flap coverage: After anastomosis, the C-shaped flap is sutured over the anastomotic site, reinforcing it by covering both the esophageal stump and the gastric window, which helps prevent complications like leakage or reflux.

PROCEDURENormal Reconstruction

1\. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall. 2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques.

Sponsors

Daorong Wang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age between 18-80 years old, male or female; 2. Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer: Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) according to the eighth edition of the AJCC ; 3. No distant metastasis was observed on preoperative chest radiograph, abdominal ultrasound, or upper abdominal CT; 4. ASA grade 1-3; 5. Patients without contraindications to surgery; 6. Patients and their families voluntarily signed the informed consent form and participated in the study;

Exclusion criteria

1. Patients diagnosed with primary tumors or distant metastasis; 2. Patients whose tumor is located in the greater curvature side of the stomach; 3. Patients with coagulation dysfunction that could not be corrected; 4. Patients who were diagnosed with viral hepatitis and cirrhosis; 5. Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin; 6. Patients with organ failure such as heart, lung, liver, brain, and kidney failure; 7. Patients with ascites or cachexia preoperatively in poor general conditions; 8. Patients diagnosed with immunodeficiency, immunosuppression, or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.). 9. Patients refusing to sign the informed consent of the study;

Design outcomes

Primary

MeasureTime frameDescription
incidence of reflux esophagitis6 months after surgeryThe percentage (%) of patients developing postoperative reflux esophagitis after surgery in each group.

Secondary

MeasureTime frameDescription
incidence of anastomotic leakage30 days after surgeryThe percentage (%) of patients developing postoperative anastomotic leakage after surgery in each group.

Countries

China

Contacts

Primary ContactDaorong Wang, doctor
wdaorong666@sina.com8618051062590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026